Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Research & Development (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Research & Development for 5 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 55.92% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.8 million through Dec 2025, down 20.56% year-over-year, with the annual reading at $44.8 million for FY2025, 20.56% down from the prior year.
  • Research & Development for Q4 2025 was $6.9 million at Werewolf Therapeutics, down from $11.6 million in the prior quarter.
  • The five-year high for Research & Development was $15.9 million in Q4 2022, with the low at $4.8 million in Q1 2021.
  • Average Research & Development over 5 years is $11.6 million, with a median of $12.1 million recorded in 2023.
  • The sharpest move saw Research & Development surged 127.22% in 2022, then crashed 55.92% in 2025.
  • Over 5 years, Research & Development stood at $13.4 million in 2021, then increased by 18.35% to $15.9 million in 2022, then crashed by 39.16% to $9.6 million in 2023, then surged by 62.99% to $15.7 million in 2024, then plummeted by 55.92% to $6.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $6.9 million, $11.6 million, and $13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.